A Multicenter Cohort Study Evaluating the Teratogenic Effects of Isotretinoin on Neonates
- PMID: 36360340
- PMCID: PMC9688499
- DOI: 10.3390/children9111612
A Multicenter Cohort Study Evaluating the Teratogenic Effects of Isotretinoin on Neonates
Abstract
(1) Background: Isotretinoin (ISO) is a systemic retinoid known for its teratogenic effects on embryos and fetuses. The aim of this study was to compare the pregnancy outcomes of women who were exposed to isotretinoin with those of women without such exposure from a teratogenic point of view. (2) Methods: A total of 1459 female patients from three clinical hospitals in Poland and Romania, segregated into two groups depending on their ISO exposure, were evaluated between January and December 2019. Medical records were screened to identify the pregnancy outcomes and congenital malformation rates. (3) Results: The congenital malformation rate for the exposed group was 1.2% (four cases), and no specific signs of Accutane embryopathy were identified. Women from the unexposed group were more likely to deliver preterm and through cesarean deliveries and had a higher rate of newborn congenital malformations as compared to women from the exposed group. (4) Conclusions: Even though we could not find a significant association between ISO exposure and teratogenic effects in newborns, effective contraceptive measures are key to preventing unfavorable pregnancy outcomes.
Keywords: contraception; isotretinoin; pregnancy outcomes; teratogenic effect.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Isotretinoin exposure during pregnancy: assessment of spontaneous reports in France.Drug Saf. 2010 Aug 1;33(8):659-65. doi: 10.2165/11536250-000000000-00000. Drug Saf. 2010. PMID: 20635824
-
Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance.Pharmacoepidemiol Drug Saf. 2019 Sep;28(9):1211-1221. doi: 10.1002/pds.4794. Epub 2019 Jul 22. Pharmacoepidemiol Drug Saf. 2019. PMID: 31328328 Free PMC article.
-
Congenital microtia in a neonate due to maternal isotretinoin exposure 1 month before pregnancy: Case Report.J Obstet Gynaecol Res. 2015 Jun;41(6):975-8. doi: 10.1111/jog.12644. Epub 2015 Mar 15. J Obstet Gynaecol Res. 2015. PMID: 25773513
-
[Isotretinoin (RoAccutane) embryopathy. A case report].J Gynecol Obstet Biol Reprod (Paris). 1995;24(5):511-5. J Gynecol Obstet Biol Reprod (Paris). 1995. PMID: 7499738 Review. French.
-
[In utero exposure to benzodiazepine. Is there a risk for anal atresia with lorazepam?].Encephale. 2003 Nov-Dec;29(6):553-9. Encephale. 2003. PMID: 15029090 Review. French.
References
-
- Food and Drug Administration (FDA) Roche Pharmaceuticals–Accutane Leaflet. [(accessed on 13 September 2022)];2002 Available online: https://wwwaccessdatafdagov/drugsatfda_docs/label/2008/018662s059lblpdf.
-
- Uysal P.I. Rapid-onset oral isotretinoin-induced acne fulminans apid-onset oral isotretinoin-induced acne fulminans without systemic symptoms in a male adolescent. Our Dermatol. Online. 2021;12:417–418. doi: 10.7241/ourd.20214.14. - DOI
-
- Tounkara T.M.B.H., Soumah M.M., Bangoura M., Diané B.F., Keita M., Kanté M.D., Traoré F.A., Sako F.B., Touré M., Doumbouya A., et al. Severe cutaneous drug reactions in Guinean children: A monocentric retrospective study of 35 cases. Our Dermatol. Online. 2018;9:118–122. doi: 10.7241/ourd.20182.3. - DOI
-
- Cammarata-Scalisi F., Nieves D., Avendaño A., Lacruz-Rengel M.A., Alviárez K., Dávila F., Yavuz I., Callea M. Isotretinoin embryopathy: An entity that can be avoided. Arch Argent Pediatr. 2018;116:e303–e307. - PubMed
LinkOut - more resources
Full Text Sources